EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Immunotherapy and the novel therapeutic development for small-cell lung cancer

Midori Matsuo iD, Hirokazu Taniguchi iD, Shinnosuke Takemoto, Keisuke Mine, Takahito Fukuda, Fumiko Hayashi, Sawana Ono, Kazumasa Akagi, Hiromi Tomono, Noritaka Honda, Yosuke Dotsu iD, Kazuto Ashizawa und 1 weitere

Therapeutic Advances in Medical Oncology · 2026-07 · 18

DOI: 10.1177/17588359261466640 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 27.07.2026. Verfasst von Midori Matsuo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small-cell lung cancer (SCLC) is broadly classified into limited- (LS) and extensive-stage (ES) disease, with distinct therapeutic approaches and outcomes. Despite high initial response rates, most patients eventually experience disease progression, particularly in the ES setting, where effective treatment options remain limited. For several decades, platinum–etoposide-based chemotherapy has remained the cornerstone of treatment, with modest improvements in overall survival. Recent advances in cancer immunology have led to the incorporation of immune checkpoint inhibitors as the first-line treatment for many cancers, representing the first major therapeutic breakthrough for SCLC. In ES-SCLC, the addition of programmed death-ligand 1 (PD-L1) inhibitors to platinum–etoposide chemotherapy has become the standard first-line approach based on the survival benefits demonstrated in phase III trials. In LS-SCLC, a consolidation PD-L1 inhibitor following definitive chemoradiotherapy has recently emerged as a new standard, as highlighted by the ADRIATIC trial, which demonstrated a significant survival advantage with durvalumab. Despite these advances, the prognosis of ES-SCLC remains poor with limited response durability and lack of robust predictive biomarkers. Tumor heterogeneity, dynamic phenotypic plasticity, and the absence of actionable genomic alterations continue to hinder precision treatment strategies. In relapse settings, novel antibody-based therapies have begun to reshape the therapeutic landscape. Delta-like ligand 3 (DLL3)-targeted T-cell engagers and antibody–drug conjugates directed against DLL3 and B7-H3 have shown encouraging antitumor activity in heavily pretreated patients, with some agents advancing to late-phase clinical evaluations. This review summarizes the systemic therapies for SCLC, focusing on recent advances in immunotherapy and emerging antibody-based strategies. This review discusses current challenges, including treatment resistance, toxicity, and biomarker development, and highlights future perspectives aimed at enabling more personalized and effective therapeutic approaches for patients with this historically aggressive disease.

Schlagwörter

Stichwörter der Autor:innen

DLL3antibody–drug conjugatesbiomarkerschemoimmunotherapysmall-cell lung cancer

Autor:innen und Institutionen

  • Clinical Research Center, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan.
  • Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan.
  • Clinical Oncology Center, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan.
  • Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan.

ORCID-Profile: Midori Matsuo, Hirokazu Taniguchi, Yosuke Dotsu

Zitieren

APA

Matsuo, M., Taniguchi, H., Takemoto, S., Mine, K., Fukuda, T., Hayashi, F., Ono, S., Akagi, K., Tomono, H., Honda, N., Dotsu, Y., Ashizawa, K., & Mukae, H. (2026). Immunotherapy and the novel therapeutic development for small-cell lung cancer. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261466640

Vancouver

Matsuo M, Taniguchi H, Takemoto S, Mine K, Fukuda T, Hayashi F, et al. Immunotherapy and the novel therapeutic development for small-cell lung cancer. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261466640

BibTeX
@article{Matsuo2026,
  author = {Matsuo, Midori and Taniguchi, Hirokazu and Takemoto, Shinnosuke and Mine, Keisuke and Fukuda, Takahito and Hayashi, Fumiko and Ono, Sawana and Akagi, Kazumasa and Tomono, Hiromi and Honda, Noritaka and Dotsu, Yosuke and Ashizawa, Kazuto and Mukae, Hiroshi},
  title = {Immunotherapy and the novel therapeutic development for small-cell lung cancer},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261466640}
}
Kostenlos starten →